Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $0.73.

  • Fortress Biotech's Debt to Equity rose 11779.14% to $0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.73, marking a year-over-year increase of 11779.14%. This contributed to the annual value of $2.55 for FY2024, which is 556.4% down from last year.
  • Latest data reveals that Fortress Biotech reported Debt to Equity of $0.73 as of Q3 2025, which was up 11779.14% from $1.14 recorded in Q2 2025.
  • Fortress Biotech's 5-year Debt to Equity high stood at $4.54 for Q1 2023, and its period low was -$15.6 during Q1 2024.
  • Moreover, its 5-year median value for Debt to Equity was $0.44 (2022), whereas its average is -$0.67.
  • The largest annual percentage gain for Fortress Biotech's Debt to Equity in the last 5 years was 93413.56% (2023), contrasted with its biggest fall of 59057.03% (2023).
  • Quarter analysis of 5 years shows Fortress Biotech's Debt to Equity stood at $0.19 in 2021, then surged by 864.64% to $1.83 in 2022, then skyrocketed by 47.21% to $2.7 in 2023, then decreased by 5.56% to $2.55 in 2024, then crashed by 71.25% to $0.73 in 2025.
  • Its Debt to Equity stands at $0.73 for Q3 2025, versus $1.14 for Q2 2025 and $1.74 for Q1 2025.